LncRNA RUNX1-IT1 affects the differentiation of Th1 cells by regulating NrCAM transcription in Graves' disease. Issue 9 (3rd May 2022)

• Record Type: Journal Article
• Authors: Huang, Feng-Jiao; Liu, Yan-Ling; Wang, Jiao; Zhou, Ying-Ying; Zhao, Shui-Ying; Qin, Gui-Jun
• Is Part Of: Cell cycle. Volume 21:Issue 9(2022)
• Page Start: 921
• Page End: 933
• Publication Date: 2022-05-03
• Subjects: Graves' disease -- lncRNA RUNX1-IT1 -- Th1 cells -- NrCAM; Cell cycle -- Periodicals; 571.84377
• DOI: 10.1080/15384101.2022.2034431
• Languages: English
• ISSNs: 1538-4101

Abstract

ABSTRACT: Graves' disease (GD) is a kind of autoimmune diseases. The development of GD is closely related to the imbalance of Th1/Th2 generated by the differentiation of CD4 + T cells. This study was sought to clarify the role of lncRNA RUNX1-IT1 and explore the mechanism of its function. The expressions of RUNX1-IT1 and Neural cell adhesion molecule (NrCAM) in the peripheral blood of GD patients were detected by qRT-PCR and Western blot. We performed RNA pull down, RIP, and ChIP experiments to verify the correlation between p53 and RUNX1-IT1, p53 and NrCAM. The levels of Th1 cells differentiation markers were detected by Flow cytometry assay and ELISA. The expressions of lncRNA RUNX1-IT1 and NrCAM were most significantly up-regulated in CD4 + T cells of GD patients, and NrCAM expression was significantly positively correlated with RUNX1-IT1 expression. Furthermore, p53 was a potential transcription factor of NrCAM, which could interact with NrCAM. NrCAM level was up-regulated after the overexpression of p53 in CD4 + T cells, while knockdown of RUNX1-IT1 reversed this effect. Down-regulation of NrCAM and RUNX1-IT1 could decrease the mRNA and protein levels of transcriptional regulator T-bet and CXC chemokine ligand 10 (CXCL10) in CD4 + T cells. Our results suggested that RUNX1-IT1 regulated the expressions of the important Th1 factor T-bet, CXCL10, and interferon γ (IFN-γ) by regulating NrCAM transcription, thus participating in the occurrence and development of specific autoimmune disease GD.